Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05947851
Registration number
NCT05947851
Ethics application status
Date submitted
7/07/2023
Date registered
17/07/2023
Date last updated
19/07/2024
Titles & IDs
Public title
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)
Query!
Scientific title
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Query!
Secondary ID [1]
0
0
MK-1026-010
Query!
Secondary ID [2]
0
0
1026-010
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Nemtabrutinib
Treatment: Drugs - Venetoclax
Treatment: Other - Rituximab
Experimental: Nemtabrutinib + Venetoclax - Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks.
Active comparator: Venetoclax + Rituximab - Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m\^2 up to 500 mg/m2 intravenous infusion once per 28-day cycle starting at C2D1, for 6 total cycles. Treatment will continue until progressive disease (PD) or discontinuation.
Treatment: Drugs: Nemtabrutinib
5 and 20 mg tablets
Treatment: Drugs: Venetoclax
10, 50, and 100 mg tablets
Treatment: Other: Rituximab
100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
Query!
Assessment method [1]
0
0
DLT evaluation period is defined as 8 weeks after the first dose of the combination treatment of nemtabrutinib plus venetoclax Cycle 2 Day 1 in Part 1 + 4 weeks follow up. Each cycle is 4 weeks. DLTs are: Grade =3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting =72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting \>7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for \>1 week (with exceptions); missing \>25% of nemtabrutinib or venetoclax doses as a result of drug-related adverse events during the first 2 cycles; Grade 5 toxicity.
Query!
Timepoint [1]
0
0
Up to approximately 12 Weeks
Query!
Primary outcome [2]
0
0
Part 1: Number of participants experiencing adverse events (AEs)
Query!
Assessment method [2]
0
0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.
Query!
Timepoint [2]
0
0
Up to approximately 28 months
Query!
Primary outcome [3]
0
0
Part 1: Number of participants discontinuing study treatment due to AEs
Query!
Assessment method [3]
0
0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 1.
Query!
Timepoint [3]
0
0
Up to approximately 25 months
Query!
Primary outcome [4]
0
0
Part 2: PFS per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as assessed by Blinded Independent Central Review (BICR)
Query!
Assessment method [4]
0
0
PFS is defined as the time from randomization to the first documented disease progression per iwCLL criteria 2018 as accessed by BICR, or death due to any cause, whichever occurs first. PFS will be presented.
Query!
Timepoint [4]
0
0
Up to approximately 71 months
Query!
Secondary outcome [1]
0
0
Part 2: Undetectable minimal residual disease (MRD) rate in bone marrow as assessed by central laboratory
Query!
Assessment method [1]
0
0
Undetectable MRD, defined as \<1 leukemic cell per 10,000 cells (MRD \<10-4) in bone marrow. The MRD rate will be presented.
Query!
Timepoint [1]
0
0
Month 14
Query!
Secondary outcome [2]
0
0
Part 2: Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS, defined as the time from randomization to death due to any cause. OS will be presented.
Query!
Timepoint [2]
0
0
Up to approximately 108 months
Query!
Secondary outcome [3]
0
0
Part 2: Objective Response Rate (ORR) per iwCLL Criteria 2018 as assessed by BICR
Query!
Assessment method [3]
0
0
OR, defined as complete response/remission (CR), complete response with incomplete count recovery (CRi), nodular partial remission (nPR), or partial remission (PR). CR is defined as meeting the following criteria: no lymph nodes \>1.5 cm, spleen size \<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets =100 x 10\^9/L; hemoglobin =11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as =50% decrease in =2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS =1 of the following met: platelets =100 x 10\^9/L or =50% increase from screening, hemoglobin \>11 g/dL or =50% increase from screening, CLL cells or B lymphoid nodules in marrow. ORR will be presented.
Query!
Timepoint [3]
0
0
Up to approximately 108 months
Query!
Secondary outcome [4]
0
0
Part 2: Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR
Query!
Assessment method [4]
0
0
DOR, defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes \>1.5 cm, spleen size \<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets =100 x 10\^9/L; hemoglobin =11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as =50% decrease in =2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS =1 of the following met: platelets =100 x 10\^9/L or =50% increase from screening, hemoglobin \>11 g/dL or =50% increase from screening, CLL cells or B lymphoid nodules in marrow. DOR will be presented.
Query!
Timepoint [4]
0
0
Up to approximately 108 months
Query!
Secondary outcome [5]
0
0
Part 2: Number of participants experiencing AEs
Query!
Assessment method [5]
0
0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.
Query!
Timepoint [5]
0
0
Up to approximately 28 months
Query!
Secondary outcome [6]
0
0
Part 2: Number of participants discontinuing study treatment due to AEs
Query!
Assessment method [6]
0
0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 2.
Query!
Timepoint [6]
0
0
Up to approximately 25 months
Query!
Eligibility
Key inclusion criteria
* Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy.
* Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, immunoglobulin heavy chain gene (IGHV) mutation status and Bruton's tyrosine kinase (BTK)-C481 mutation status results required before randomization for Part 2 participants only.
* Relapsed or refractory to at least 1 prior available therapy.
* Have at least 1 marker of disease burden.
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.
* Has a life expectancy of at least 3 months.
* Has the ability to swallow and retain oral medication.
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.
* Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.
* Participants with adequate organ function with specimens collected within 7 days before the start of study intervention.
* If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar): not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception.
* Participant assigned female sex at birth are eligible to participate if not pregnant or breastfeeding and are not a person of childbearing potential (POCBP) OR is a POCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.
* Has gastrointestinal (GI) dysfunction that may affect drug absorption.
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.
* Has an active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening.
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease and/or acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.
* Has QT interval corrected (QTc) prolongation or other significant electrocardiogram (ECG) abnormalities.
* Has a known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients.
* Has history of severe bleeding disorders (eg, hemophilia).
* Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization.
* Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) including venetoclax or Non-covalent Bruton's tyrosine kinase inhibitor (BTKi).
* Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.
* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention.
* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.
* Has a known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
* Participants who have not adequately recovered from major surgery or have ongoing surgical complications.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/08/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
27/06/2033
Query!
Actual
Query!
Sample size
Target
720
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
Royal Adelaide Hospital ( Site 1104) - Adelaide
Query!
Recruitment hospital [2]
0
0
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103) - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3021 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Washington
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Wisconsin
Query!
Country [6]
0
0
Argentina
Query!
State/province [6]
0
0
Buenos Aires
Query!
Country [7]
0
0
Argentina
Query!
State/province [7]
0
0
Caba
Query!
Country [8]
0
0
Argentina
Query!
State/province [8]
0
0
Santa Fe
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Vlaams-Brabant
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Sao Paulo
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
New Brunswick
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Quebec
Query!
Country [13]
0
0
Chile
Query!
State/province [13]
0
0
Biobio
Query!
Country [14]
0
0
Chile
Query!
State/province [14]
0
0
Coquimbo
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Region M. De Santiago
Query!
Country [16]
0
0
Colombia
Query!
State/province [16]
0
0
Valle Del Cauca
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Nord
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Puy-de-Dome
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Vendee
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Rheinland-Pfalz
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Sachsen
Query!
Country [22]
0
0
Israel
Query!
State/province [22]
0
0
Haifa
Query!
Country [23]
0
0
Israel
Query!
State/province [23]
0
0
Jerusalem
Query!
Country [24]
0
0
Israel
Query!
State/province [24]
0
0
Ramat Gan
Query!
Country [25]
0
0
Israel
Query!
State/province [25]
0
0
Tel Aviv
Query!
Country [26]
0
0
Italy
Query!
State/province [26]
0
0
Alessandria
Query!
Country [27]
0
0
Italy
Query!
State/province [27]
0
0
Milano
Query!
Country [28]
0
0
Italy
Query!
State/province [28]
0
0
Reggio Emilia
Query!
Country [29]
0
0
Puerto Rico
Query!
State/province [29]
0
0
San Juan
Query!
Country [30]
0
0
South Africa
Query!
State/province [30]
0
0
Gauteng
Query!
Country [31]
0
0
South Africa
Query!
State/province [31]
0
0
Western Cape
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Barcelona
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Madrid
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Valenciana, Comunitat
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
England
Query!
Country [36]
0
0
United Kingdom
Query!
State/province [36]
0
0
London, City Of
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Query!
Trial website
https://clinicaltrials.gov/study/NCT05947851
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Toll Free Number
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-577-8839
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05947851
Download to PDF